Galera Therapeutics Financials
We strongly advise to harness Galera Therapeutics fundamental analysis to find out if markets are presently mispricing the company. Simply put you can make use of it to find out if Galera Therapeutics is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to interpolate and analyze data for thirty-two available reported financial drivers for Galera Therapeutics, which can be compared to its competitors.
Galera |
Understanding current and past Galera Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Galera Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Galera Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Galera Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Galera Therapeutics. Check Galera Therapeutics' Beneish M Score to see the likelihood of Galera Therapeutics' management manipulating its earnings.
Galera Therapeutics Stock Summary
Galera Therapeutics competes with Mereo BioPharma, Terns Pharmaceuticals, PDS Biotechnology, Inozyme Pharma, and Hookipa Pharma. Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Galera Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.Specialization | Healthcare, Biotechnology |
| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US36338D1081 |
| CUSIP | 36338D108 |
| Location | Pennsylvania; U.S.A |
| Business Address | PO Box 134, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.galeratx.com |
| Phone | 610 725 1500 |
| Currency | USD - US Dollar |
Galera Therapeutics Key Financial Ratios
Galera Therapeutics' financial ratios allow both analysts and investors to convert raw data from Galera Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Galera Therapeutics over time and compare it to other companies across industries.| Return On Equity | -10.63 | ||||
| Return On Asset | -0.59 | ||||
| Target Price | 0.5 | ||||
| Beta | 2.03 |
Galera Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Galera Therapeutics's current stock value. Our valuation model uses many indicators to compare Galera Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Galera Therapeutics competition to find correlations between indicators driving Galera Therapeutics's intrinsic value. More Info.Galera Therapeutics is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Galera Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Galera Therapeutics' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in Galera Pink Sheet
If you are still planning to invest in Galera Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Galera Therapeutics' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |